Physician profile
Andrew Jin
NPI 1083173280
$1,618.95
in general payments reported to CMS, 2019-2025
11 companies · $374 in 2025
The $374 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.33 · 2023: $564 · 2024: $665 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,602.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $431.58 | 2024 | Stellaris |
| Alimera Sciences, INC. | $251.39 | 2023 | Iluvien |
| Neurotech Pharmaceuticals, INC. | $219.66 | 2025 | |
| Carl Zeiss Meditec Cataract Technology INC. | $192.37 | 2023 | |
| Dompe US, INC. | $120.90 | 2025 | Oxervate |
| Abbvie INC. | $120.43 | 2024 | |
| Alcon Vision LLC | $114.66 | 2022-2023 | Hydrus Microstent |
| Johnson & Johnson Surgical Vision, INC. | $84.89 | 2024 | Tecnis Simplicity |
| Astellas Pharma US INC | $33.01 | 2025 | Izervay |
| Dutch Ophthalmic, USA | $28.47 | 2024 | Eva, Combined Machine, Tissueblue |
| Glaukos Corporation | $21.59 | 2023 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Jin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.